AstraZeneca buys drugmaker Caelum in deal worth up to $500 million - NewsBreak

(Reuters) - AstraZeneca said on Wednesday its newly acquired Alexion division will purchase the remaining equity in drugmaker Caelum Biosciences in a deal that could be worth up to $500 million, expanding its access into rare-disease treatments. The Anglo-Swedish drugmaker said it would take forward Caelum's late-stage trial of a...